Aprepitant + Placebo
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Chemotherapy Induced Nausea and Vomiting
Conditions
Chemotherapy Induced Nausea and Vomiting
Trial Timeline
Aug 1, 2011 → Jun 1, 2013
NCT ID
NCT01402024About Aprepitant + Placebo
Aprepitant + Placebo is a phase 3 stage product being developed by Dr. Reddy's Laboratories for Chemotherapy Induced Nausea and Vomiting. The current trial status is completed. This product is registered under clinical trial identifier NCT01402024. Target conditions include Chemotherapy Induced Nausea and Vomiting.
What happened to similar drugs?
3 of 20 similar drugs in Chemotherapy Induced Nausea and Vomiting were approved
Approved (3) Terminated (4) Active (14)
🔄recombinant human erythropoietin + recombinant human erythropoietin placeboChugai PharmaceuticalPhase 3
🔄olanzapine plus fosaprepitant-based triple regimen + placebo plus fosaprepitant-based triple regimenSun PharmaceuticalPhase 3
Hype Score Breakdown
Clinical
17
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01402024 | Phase 3 | Completed |
Competing Products
20 competing products in Chemotherapy Induced Nausea and Vomiting